Compare GKOS & OTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | OTEX |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2015 | 1998 |
| Metric | GKOS | OTEX |
|---|---|---|
| Price | $100.96 | $22.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 10 |
| Target Price | ★ $133.07 | $37.50 |
| AVG Volume (30 Days) | 577.7K | ★ 1.7M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 4.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.24 |
| Revenue | $507,442,000.00 | ★ $2,815,241,000.00 |
| Revenue This Year | $23.34 | $2.80 |
| Revenue Next Year | $27.46 | $1.05 |
| P/E Ratio | ★ N/A | $18.22 |
| Revenue Growth | ★ 32.33 | 22.88 |
| 52 Week Low | $73.16 | $22.26 |
| 52 Week High | $130.23 | $39.90 |
| Indicator | GKOS | OTEX |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 34.66 |
| Support Level | $94.92 | $22.44 |
| Resistance Level | $104.66 | $33.67 |
| Average True Range (ATR) | 4.02 | 0.78 |
| MACD | -0.71 | -0.08 |
| Stochastic Oscillator | 22.45 | 15.90 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.